COMBIGAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Combigan, and what generic alternatives are available?
Combigan is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in COMBIGAN is brimonidine tartrate; timolol maleate. There are eleven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate; timolol maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Combigan
A generic version of COMBIGAN was approved as brimonidine tartrate; timolol maleate by SANDOZ on April 4th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for COMBIGAN?
- What are the global sales for COMBIGAN?
- What is Average Wholesale Price for COMBIGAN?
Summary for COMBIGAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Clinical Trials: | 22 |
Patent Applications: | 42 |
Drug Prices: | Drug price information for COMBIGAN |
Drug Sales Revenues: | Drug sales revenues for COMBIGAN |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for COMBIGAN |
What excipients (inactive ingredients) are in COMBIGAN? | COMBIGAN excipients list |
DailyMed Link: | COMBIGAN at DailyMed |
Recent Clinical Trials for COMBIGAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hanlim Pharm. Co., Ltd. | Phase 4 |
CHA University | Phase 4 |
Salus University | Phase 4 |
Pharmacology for COMBIGAN
Drug Class | alpha-Adrenergic Agonist beta-Adrenergic Blocker |
Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Antagonists |
Paragraph IV (Patent) Challenges for COMBIGAN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
COMBIGAN | Ophthalmic Solution | brimonidine tartrate; timolol maleate | 0.2%/0.5% | 021398 | 1 | 2008-11-21 |
US Patents and Regulatory Information for COMBIGAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | COMBIGAN | brimonidine tartrate; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 021398-001 | Oct 30, 2007 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COMBIGAN
International Patents for COMBIGAN
See the table below for patents covering COMBIGAN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1114048 | ⤷ Sign Up | |
China | 1516588 | 用于局部眼科应用的溴莫尼定和噻吗洛尔的组合 (Combination of brimonidine and timolol for topical ophthalmic use) | ⤷ Sign Up |
China | 100558364 | ⤷ Sign Up | |
China | 112219061 | 带有声音抑制的悬挂式垂饰光导灯具 (SUSPENDED PENDANT LIGHTGUIDE LUMINAIRE WITH SOUND DAMPENING) | ⤷ Sign Up |
Hong Kong | 1067549 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE | ⤷ Sign Up |
South Korea | 20040100844 | ⤷ Sign Up | |
Brazil | 0302584 | Combinação de brimonidina e timolol para uso oftálmico tópico | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for COMBIGAN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1631293 | 2014C/042 | Belgium | ⤷ Sign Up | PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221 |
1631293 | 92462 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225 |
1631293 | 2014/041 | Ireland | ⤷ Sign Up | PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221 |
1631293 | 300683 | Netherlands | ⤷ Sign Up | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
1631293 | C300683 | Netherlands | ⤷ Sign Up | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
1631293 | 14C0056 | France | ⤷ Sign Up | PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |